Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 studyPaolo F. Caimi, Carmelo Carlo‐Stella, Mehdi Hamadani et al.|Haematologica|2023Cited by 37
P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|HemaSphere|2023Cited by 3